Print

Tengion Inc. to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference  
2/5/2013 6:59:56 AM

WINSTON-SALEM, N.C., Feb. 5, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that A. Brian Davis, Chief Financial Officer and Vice President, Finance of Tengion, will present at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:30 a.m. EST in New York City.

A live audio webcast of the presentation can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2013/23210244.cfm or under "Calendar of Events" in the Investors & News section of the Company's website at www.tengion.com. A replay of the presentation will be available on Tengion's website for 90 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

SOURCE Tengion, Inc.


//-->